Citronbaum R
Med Pediatr Oncol. 1978;4(4):363-6. doi: 10.1002/mpo.2950040413.
Nine patients with "limited" (thoracic) small-cell lung carcinoma were treated with combined chemotherapy and radiotherapy (involved field and prophylactic whole brain). Induction drugs were Vincristine, Adriamycin, and Cyclophosphamide; and Cyclophosphamide, Vincristine, and CCNU for maintenance. Eight out of nine patients (89%) continue NED at a median follow-up time of 12 months. This group is compared to 21 patients with more extensive disease and 6 patients with limited disease using various other regimens. Median survival in the extensive group was 5 months and 8 months for the limited-diseased group treated with single agents. Intensive combination chemo-irradiation therapy is safe and highly effective in patients with limited oat-cell carcinoma of the lung, and leads to prolonged disease-free survival.
9例“局限期”（胸段）小细胞肺癌患者接受了化疗联合放疗（累及野及全脑预防性照射）。诱导化疗药物为长春新碱、阿霉素和环磷酰胺；维持化疗药物为环磷酰胺、长春新碱和洛莫司汀。9例患者中有8例（89%）在中位随访时间12个月时仍处于无疾病证据（NED）状态。将该组患者与另外21例病情更广泛的患者以及6例采用其他各种方案治疗的局限期患者进行了比较。广泛期组的中位生存期为5个月，单药治疗的局限期组为8个月。强化联合放化疗对局限期肺燕麦细胞癌患者安全且高效，可延长无病生存期。
